OmniAb, Inc. OABI
- Market cap
- $697.9M
- P/E
- 0.0×
Follow OABI
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | 9.75 | 1.91 | 3.07 | 3.43 | 1.22 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | — | — | — | — | 10.50 | 10.50 | 6.20 | 6.72 | 4.02 |
High Price
|
|||
| — | — | — | — | — | 0 | 95 | 106 | 114 | 89 |
Employees
|
|||
| — | — | — | — | — | 0 | 1 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| — | — | — | — | — | 35 | 59 | 34 | 26 | 19 |
Revenue
|
|||
| — | — | — | — | — | 100.00% | 100.00% | 100.00% | 100.00% | 98.38% |
Gross Margin
|
|||
| — | — | — | — | — | (34) | (26) | (64) | (71) | (66) |
EBT
|
|||
| — | — | — | — | — | (98.85%) | (44.11%) | (188.39%) | (270.59%) | (355.16%) |
EBT Margin
|
|||
| — | 0 | — | — | — | (27) | (22) | (51) | (62) | (65) |
Net Income
|
|||
| — | — | — | — | — | 16 | 18 | 16 | 22 | 21 |
Depreciation
|
|||
| — | — | — | — | — | 0.42 | 0.69 | 0.34 | 0.26 | 0.16 |
Revenue/Sh
|
|||
| — | — | — | — | — | (0.33) | (0.26) | (0.51) | (0.61) | (0.57) |
Earnings/Sh
|
|||
| — | — | — | — | — | (0.07) | (0.04) | 0.02 | (0.39) | (0.32) |
Cash Flow/Sh
|
|||
| — | — | — | — | — | (0.05) | (0.20) | (0.02) | (0.02) | 0.02 |
Capex/Sh
|
|||
| — | — | — | — | — | (0.12) | (0.24) | 0.01 | (0.41) | (0.30) |
Free CF/Sh
|
|||
| — | — | — | — | — | 2.84 | 4.00 | 3.16 | 2.81 | 2.35 |
Book Value/Sh
|
|||
| — | — | — | — | — | 83 | 85 | 100 | 102 | 114 |
Shares
|
|||
| — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| — | — | — | — | — | 0.00 | 5.01 | 18.24 | 13.73 | 11.26 |
PS Ratio
|
|||
| — | — | — | — | — | 3.53 | 0.87 | 1.98 | 1.26 | 0.79 |
PB Ratio
|
|||
| — | — | — | — | — | 0.00 | 3.52 | 15.69 | 11.48 | 8.37 |
EV/Sales
|
|||
| — | — | — | — | — | (145.62) | (10.01) | 762.50 | (7.29) | (4.59) |
EV/FCF
|
|||
| — | — | — | — | — | (6) | (4) | 2 | (40) | (36) |
Op' Cash Flow
|
|||
| — | — | — | — | — | (4) | (17) | (2) | (2) | 2 |
Capex
|
|||
| — | — | — | — | — | (10) | (21) | 1 | (42) | (34) |
FCF
|
|||
| — | — | — | — | — | 2 | 99 | 72 | 53 | 49 |
Working Cap'
|
|||
| — | — | — | — | — | 14 | 26 | — | — | — |
Total Debt
|
|||
| — | — | — | — | — | 0 | (88) | (87) | (59) | (54) |
Net Debt
|
|||
| — | — | — | — | — | 234 | 341 | 315 | 288 | 267 |
Sh' Equity
|
|||
| — | — | — | — | — | (17.76%) | (6.16%) | (12.71%) | (17.70%) | (20.68%) |
ROA
|
|||
| — | — | — | — | — | (9.51%) | (6.58%) | (19.06%) | (20.41%) | (20.24%) |
ROIC
|
|||
| — | — | — | — | — | 0.00% | (7.76%) | (15.43%) | (20.60%) | (23.36%) |
ROE
|
|||
OmniAb, Inc. peers in Biotechnology
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| SLN Silence Therapeutics PLC Sponsored ADR | $697.3M | 0.0× | Compare |
| VSTM Verastem, Inc. | $694.6M | 0.0× | Compare |
| NVCT Nuvectis Pharma, Inc. | $706.1M | 0.0× | Compare |
| MDXG MiMedx Group, Inc | $686.5M | 117× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| DNA Ginkgo Bioworks Holdings, Inc. | $683.6M | 0.0× | Compare |
| CLYM Climb Bio, Inc. | $682.9M | 0.0× | Compare |
| ANNX Annexon, Inc. | $720.4M | 0.0× | Compare |
| ZVRA Zevra Therapeutics, Inc. | $668.7M | 11.6× | Compare |
OmniAb, Inc. (OABI) key facts
- OmniAb, Inc. (OABI) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- OmniAb, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $18.7 million, down 29.3% from fiscal 2024.
- OmniAb, Inc. reported a net loss of $64.8 million, or a loss of $0.57 per share, for fiscal 2025.
- As of September 25, 2026, OABI traded at $4.61, a market capitalization of $697.9 million.
- Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 15.4× sales.
- Return on equity was −23.4% and debt-to-equity 0.00.
OmniAb, Inc. (OABI) Latest News
28 Aug
OmniAb partners with Eli Lilly in a deal that may prove pivotal for the company's growth and market performance. Partnership with Eli Lilly positions OmniAb for major strategic advancement and improved investor outlook.
17 Aug
OmniAb shares surged 18% after a deal with Eli Lilly improved the company's cash outlook. Lilly deal directly lifts cash position and triggers major stock movement for OmniAb.
OmniAb, Inc. (OABI) raised its 2026 financial guidance. Raising 2026 guidance signals stronger expected results and can materially lift investor sentiment and valuation.
OmniAb, Inc. announced a global collaboration and license agreement with Eli Lilly & Company for its ion channel program. Deal with Eli Lilly for ion channel program drives major revenue potential and strategic advancement for OmniAb.
OmniAb, Inc. raised its 2026 cash outlook after gaining licensing momentum. Raised cash outlook from licensing momentum signals modestly better financial prospects without altering core trajectory.
14 Aug
OmniAb held its Q2 2026 earnings call, covering financial results, operational updates, and forward outlook. Quarterly earnings calls typically provide performance data and guidance that can moderately influence near-term stock sentiment.
7 Aug
OmniAb Inc (OABI) Q2 2026 revenue surged 243% with two programs advancing significantly. 243% revenue growth and program progress indicate major positive shifts in financials and outlook.
OmniAb Inc. released Q2 earnings call highlights covering financial results, operational updates and business outlook. Quarterly earnings data and guidance directly inform near-term financial expectations and investor positioning.
6 Aug
OmniAb reported second quarter 2026 financial results and business highlights. Quarterly results deliver performance data that shapes near-term investor sentiment without signaling major strategic shifts.
27 Jul
VERAXA Biotech advances its bispecific ADC program under OmniAb collaboration. Progress in partnered ADC program validates OmniAb platform and supports modest revenue upside.
VERAXA Biotech advances bispecific antibody drug conjugate VXA-222 developed via joint discovery collaboration with OmniAb. Advancement of collaborative ADC program provides moderate validation for OmniAb antibody discovery platform.
6 Jul
VERAXA is committing fully to a cancer therapy strategy built around OmniAb's antibody discovery platform to develop novel oncology treatments. VERAXA's all-in cancer therapy bet directly expands OmniAb's oncology pipeline and revenue potential through platform licensing.
2 Jun
OmniAb (NASDAQ:OABI) ranks among companies positioned to invest in growth. Positioning for growth investments can enhance OmniAb's operational capabilities and market standing.
8 May
OmniAb (OABI) released Q1 2026 earnings call transcript detailing financial results, operational updates, and forward guidance. Q1 2026 earnings transcript discloses financial performance and strategic outlook capable of significantly swaying investor sentiment and stock trajectory.
OmniAb, Inc. released Q1 2026 earnings call summary detailing financial results, operational updates, and forward guidance. Q1 2026 earnings details financial performance and strategic outlook, likely driving significant shifts in investor sentiment and stock trajectory.
OmniAb released highlights from its Q1 earnings call, covering financial results, pipeline progress, and strategic updates. Q1 earnings highlights provide updates on financial performance and operations with moderate influence on trajectory and sentiment.
7 May
OmniAb, Inc. (OABI) reported a first-quarter net loss but surpassed Wall Street revenue estimates. Q1 net loss despite revenue beat signals mixed results with moderate effects on financial performance and market sentiment.
OmniAb, Inc. reported first quarter 2026 financial results and key business highlights. Quarterly earnings reports impact financial performance and market sentiment but are routine disclosures.
22 Apr
OmniAb, Inc. (OABI) insiders bought US$1.28 million worth of stock, signaling strong bullish confidence in the company's prospects. Insider purchases indicate optimism and may positively influence short-term market sentiment without fundamentally altering operations.
14 Apr
OmniAb, Inc. (OABI) stands well-positioned for momentum build-up in 2026. OmniAb's positioning for 2026 momentum signals moderately noticeable influence on future performance and investor sentiment.
31 Mar
OmniAb Inc. (OABI) provides a transgenic animal platform for antibody discovery with partnerships including Astellas, Takeda, and IGM Biosciences. Q2 2024 revenue rose 39% year-over-year to $10.7 million, backed by $26.8 million cash reserves. OmniAb 2.0 launched, incorporating human light chains for enhanced antibody candidates. Despite patent challenges, strong pipeline and analyst buy ratings highlight undervaluation and growth potential. Revenue surge and new platform launch moderately strengthen financials and competitive edge amid ongoing patent issues.
15 Mar
OmniAb (OABI) released Q4 2025 earnings call transcript detailing financial results, operations, and outlook. Q4 earnings transcripts disclose full-year financials, strategic updates, and guidance that significantly shape investor expectations and stock performance.
5 Mar
OmniAb, Inc. (OABI) released Q4 2025 earnings call summary covering financial results, operational updates, and forward guidance. Q4 earnings call summary discloses financial performance and strategic outlook significantly influencing OABI's trajectory and investor sentiment.
OmniAb Inc (OABI) Q4 2025 earnings call highlights strong partner engagement and new developments. Strong partner engagement in Q4 2025 earnings signals major advancements in pipeline and revenue potential.
4 Mar
OmniAb, Inc. (OABI) released highlights from its Q4 earnings call, covering financial results, pipeline progress, and strategic updates. Q4 earnings call highlights detail financial performance, partnerships, and guidance that could significantly shape investor sentiment and company trajectory.
OmniAb, Inc. (OABI) reported fourth quarter and full-year 2025 financial results alongside key business highlights. Financial results and business highlights disclosure directly shapes investor sentiment and stock trajectory.
OmniAb, Inc. (OABI) reported a Q4 loss and missed revenue estimates. Q4 loss and revenue miss highlight weaker financial results, moderately affecting investor sentiment and near-term performance.
6 Jan
OmniAb, Inc. (NASDAQ:OABI) has garnered significant interest from institutional investors, who collectively hold a substantial 36% stake in the company. This level of investment indicates a strong confidence in OmniAb's potential and future performance in the market. The substantial institutional stake suggests a significant impact on investor sentiment and potential future performance.
15 Dec
OmniAb, Inc. has launched OmniUltra, a new platform that enhances its antibody discovery capabilities and expands its market reach. This innovative technology is designed to improve the efficiency and effectiveness of antibody generation, positioning OmniAb as a leader in the field. The launch is expected to open new applications and markets for the company, further solidifying its competitive advantage in antibody discovery technologies. The launch of OmniUltra is a significant strategic move that could greatly enhance OmniAb's market position and investor sentiment.
10 Dec
OmniAb, Inc. is currently facing a cash burn situation, but analysts are not overly concerned due to the company's strong financial position and strategic initiatives. The firm has sufficient cash reserves to sustain operations while pursuing growth opportunities. Additionally, ongoing partnerships and collaborations are expected to enhance revenue streams, mitigating the impact of cash burn. Overall, the outlook remains positive as the company navigates its financial challenges. The company's cash burn is manageable due to strong financial reserves and strategic partnerships.